http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2017200047-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-416 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5355 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2017-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae0fcba75350d6ac7bcbcfde18e510ae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbfb3eff819c5d24d2d7b723e249d89e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74b5c77c25c4f55f3d3c893b4ca43b08 |
| publicationDate | 2018-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2017200047-B2 |
| titleOfInvention | Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| abstract | Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 8556883_1 (GHMatters) P85021.AU.2 i /27 SKBR3 Proliferation - 3 Days trastuzumab ca Combo: T-DM1 trastuzumab 0 T-DM1 0.25x 0.5x 1x 2x 4x Bx 16x IC50 Multiple Figure 1 BT474-EEI Proliferation - 3 Days Q trastuzumab - 0.8 Combo: T-DM1 + trastuzumab -2 0.6 0T-DM1 z 0.125x 0.25x 0.5x 1x 2x 4x 8x IC50 Multiple Figure 2 |
| priorityDate | 2008-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 645.